Works matching AU Sonneveld, Pieter

Results: 155
    1

    Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

    Published in:
    Drugs, 2016, v. 76, n. 9, p. 989, doi. 10.1007/s40265-016-0590-3
    By:
    • Moreau, Philippe;
    • Donk, Niels;
    • Miguel, Jesus;
    • Lokhorst, Henk;
    • Nahi, Hareth;
    • Ben-Yehuda, Dina;
    • Cavo, Michele;
    • Cook, Gordon;
    • Delforge, Michel;
    • Einsele, Hermann;
    • Zweegman, Sonja;
    • Ludwig, Heinz;
    • Driessen, Christoph;
    • Palumbo, Antonio;
    • Facon, Thierry;
    • Plesner, Torben;
    • Dimopoulos, Meletios;
    • Sondergeld, Pia;
    • Sonneveld, Pieter;
    • Mateos, María-Victoria
    Publication type:
    Article
    2

    Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

    Published in:
    Drugs, 2016, v. 76, n. 8, p. 853, doi. 10.1007/s40265-016-0573-4
    By:
    • Moreau, Philippe;
    • Donk, Niels;
    • Miguel, Jesus;
    • Lokhorst, Henk;
    • Nahi, Hareth;
    • Ben-Yehuda, Dina;
    • Cavo, Michele;
    • Cook, Gordon;
    • Delforge, Michel;
    • Einsele, Hermann;
    • Zweegman, Sonja;
    • Ludwig, Heinz;
    • Driessen, Christoph;
    • Palumbo, Antonio;
    • Facon, Thierry;
    • Plesner, Torben;
    • Dimopoulos, Meletios;
    • Sondergeld, Pia;
    • Sonneveld, Pieter;
    • Mateos, María-Victoria
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10

    Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.

    Published in:
    2019
    By:
    • Gambella, Manuela;
    • Omedé, Paola;
    • Spada, Stefano;
    • Muccio, Vittorio Emanuele;
    • Gilestro, Milena;
    • Saraci, Elona;
    • Grammatico, Sara;
    • Larocca, Alessandra;
    • Conticello, Concetta;
    • Bernardini, Annalisa;
    • Gamberi, Barbara;
    • Troia, Rossella;
    • Liberati, Anna Marina;
    • Offidani, Massimo;
    • Rocci, Alberto;
    • Palumbo, Antonio;
    • Cavo, Michele;
    • Sonneveld, Pieter;
    • Boccadoro, Mario;
    • Oliva, Stefania
    Publication type:
    journal article
    11

    Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

    Published in:
    2016
    By:
    • Orlowski, Robert Z.;
    • Nagler, Arnon;
    • Sonneveld, Pieter;
    • Bladé, Joan;
    • Hajek, Roman;
    • Spencer, Andrew;
    • Robak, Tadeusz;
    • Dmoszynska, Anna;
    • Horvath, Noemi;
    • Spicka, Ivan;
    • Sutherland, Heather J.;
    • Suvorov, Alexander N.;
    • Xiu, Liang;
    • Cakana, Andrew;
    • Parekh, Trilok;
    • San‐Miguel, Jesús F.
    Publication type:
    journal article
    12
    13

    Unimpaired dendritic cell functions in MVP /LRP knockout mice.

    Published in:
    Immunology, 2003, v. 110, n. 1, p. 58, doi. 10.1046/j.1365-2567.2003.01708.x
    By:
    • Mossink, Marieke H.;
    • de Groot, Jan;
    • van Zon, Arend;
    • Fränzel-Luiten, Erna;
    • Schoester, Martijn;
    • Scheffer, George L.;
    • Sonneveld, Pieter;
    • Scheper, Rik J.;
    • Wiemer, Erik A. C.
    Publication type:
    Article
    14
    15

    Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial.

    Published in:
    British Journal of Haematology, 2021, v. 193, n. 3, p. 561, doi. 10.1111/bjh.17321
    By:
    • Hungria, Vania;
    • Beksac, Meral;
    • Weisel, Katja C.;
    • Nooka, Ajay K.;
    • Masszi, Tamas;
    • Spicka, Ivan;
    • Munder, Markus;
    • Mateos, María‐Victoria;
    • Mark, Tomer M.;
    • Qi, Ming;
    • Qin, Xiang;
    • Fastenau, John;
    • Spencer, Andrew;
    • Sonneveld, Pieter;
    • Garvin, Wendy;
    • Renaud, Thomas;
    • Gries, Katharine S.
    Publication type:
    Article
    16
    17

    HOVON 104, long‐term follow‐up of bortezomib‐dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients.

    Published in:
    EJHaem, 2024, v. 5, n. 4, p. 815, doi. 10.1002/jha2.918
    By:
    • Minnema, Monique C.;
    • Nasserinejad, Kazem;
    • Hegenbart, Ute;
    • Ypma, Paula F.;
    • Wu, Ka Lung;
    • Kersten, Marie Jose;
    • Croockewit, Sandra;
    • Zweegman, Sonja;
    • Tick, Lidwine;
    • Broijl, Annemiek;
    • Koene, Harry;
    • Bos, Gerard M. J.;
    • Sonneveld, Pieter;
    • Schönland, Stefan O.
    Publication type:
    Article
    18

    Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching

    Published in:
    EJHaem, 2021, v. 2, n. 1, p. 66, doi. 10.1002/jha2.129
    By:
    • Moreau, Philippe;
    • Hulin, Cyrille;
    • Zweegman, Sonja;
    • Hashim, Mahmoud;
    • Hu, Yannan;
    • Heeg, Bart;
    • Boer, Carla;
    • Vanquickelberghe, Veronique;
    • Kampfenkel, Tobias;
    • He, Jianming;
    • Lam, Annette;
    • Cote, Sarah;
    • Sonneveld, Pieter
    Publication type:
    Article
    19

    Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible.

    Published in:
    EJHaem, 2020, v. 1, n. 2, p. 481, doi. 10.1002/jha2.77
    By:
    • Sonneveld, Pieter;
    • Mateos, María‐Victoria;
    • Alegre, Adrian;
    • Facon, Thierry;
    • Hulin, Cyrille;
    • Hashim, Mahmoud;
    • Vincken, Talitha;
    • Kampfenkel, Tobias;
    • Cote, Sarah;
    • He, Jianming;
    • Lam, Annette;
    • Moreau, Philippe
    Publication type:
    Article
    20
    21

    Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 9, p. 687, doi. 10.1016/j.clml.2023.05.004
    By:
    • Sonneveld, Pieter;
    • Richardson, Paul G.;
    • Ludwig, Heinz;
    • Dimopoulos, Meletios-Athanasios;
    • Schjesvold, Fredrik H.;
    • Hajek, Roman;
    • Abdulhaq, Haifaa;
    • Thuresson, Marcus;
    • Norin, Stefan;
    • Bakker, Nicolaas A.;
    • Mateos, Maria-Victoria
    Publication type:
    Article
    22
    23
    24
    25

    OAB-008: Identification of high-risk Multiple Myeloma with a plasma cell Leukemia-like transcriptomic profile.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S6, doi. 10.1016/S2152-2650(21)02082-6
    By:
    • Bruinink, Davine Hofste op;
    • Kuiper, Rowan;
    • Duin, Mark van;
    • Cupedo, Tom;
    • Velden, Vincent H.J. van der;
    • Hoogenboezem, Remco;
    • Holt, Bronno van der;
    • Beverloo, H. Berna;
    • Valent, Erik T.;
    • Vermeulen, Michael;
    • Gay, Francesca;
    • Broijl, Annemiek;
    • Avet-Loiseau, Hervé;
    • Munshi, Nikhil C.;
    • Musto, Pellegrino;
    • Moreau, Philippe;
    • Zweegman, Sonja;
    • Donk, Niels W.C.J. van de;
    • Sonneveld, Pieter
    Publication type:
    Article
    26
    27
    28

    Pomalidomide and Dexamethasone Treatment for ≥ 1 Year in Renally Impaired Patients With Relapsed or Refractory Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e284, doi. 10.1016/j.clml.2019.09.468
    By:
    • Weisel, Katja;
    • Dimopoulos, Meletios A.;
    • Cook, Mark;
    • Ramasamy, Karthik;
    • Rubia, Javier De La;
    • Ardizzoia, Antonio;
    • Krauth, Maria Theresa;
    • JACCARD, Arnaud;
    • Van de Donk, Niels;
    • Kueenburg, Elisabeth;
    • Di Micco, Antonia;
    • Rosettani, Barbara;
    • Atiba-Davies, Margaret;
    • Bacon, Pamela;
    • Sonneveld, Pieter
    Publication type:
    Article
    29

    Carfilzomib, bendamustine, dexamethasone in patients with advanced multiple myeloma: The EMN09 Phase I/II study of the European Myeloma Network.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e256, doi. 10.1016/j.clml.2019.09.424
    By:
    • Gramatzki, Martin;
    • Offidani, Massimo;
    • Günther, Andreas;
    • Engelhardt, Monika;
    • Salvini, Marco;
    • Montefusco, Vittorio;
    • Patriarca, Francesca;
    • Angelucci, Emanuele;
    • Poenisch, Wolfram;
    • Spada, Stefano;
    • Schub, Natalie;
    • Gentili, Silvia;
    • Wäsch, Ralph;
    • Corradini, Paolo;
    • Einsele, Hermann;
    • Boccadoro, Mario;
    • Sonneveld, Pieter;
    • Gay, Francesca
    Publication type:
    Article
    30
    31

    A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Cyclophosphamide- Dexamethasone (VCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e201, doi. 10.1016/j.clml.2019.09.335
    By:
    • Sonneveld, Pieter;
    • Dejoie, Thomas;
    • Zweegman, Sonja;
    • Merz, Maximilian;
    • Weisel, Katja;
    • Lam, Annette;
    • Krotneva, Stanimira;
    • Proskorovsky, Irina;
    • Kampfenkel, Tobias;
    • de Boer, Carla;
    • Cote, Sarah;
    • Moreau, Philippe
    Publication type:
    Article
    32

    A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e200, doi. 10.1016/j.clml.2019.09.334
    By:
    • Moreau, Philippe;
    • Attal, Michel;
    • Facon, Thierry;
    • Caillot, Denis;
    • LENAIN, Pascal;
    • Benboubker, Lofti;
    • Lam, Annette;
    • Krotneva, Stanimira;
    • Proskorovsky, Irina;
    • Kampfenkel, Tobias;
    • Vanquickelberghe, Véronique;
    • Cote, Sarah;
    • Sonneveld, Pieter
    Publication type:
    Article
    33

    A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexamethasone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e199, doi. 10.1016/j.clml.2019.09.333
    By:
    • Moreau, Philippe;
    • Attal, Michel;
    • Facon, Thierry;
    • Leleu, Xavier;
    • Hulin, Cyrille;
    • Hashim, Mahmoud;
    • Hu, Yannan;
    • Cote, Sarah;
    • Kampfenkel, Tobias;
    • de Boer, Carla;
    • Lam, Annette;
    • Sonneveld, Pieter
    Publication type:
    Article
    34
    35
    36
    37
    38

    Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and -MM5 trials.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e43, doi. 10.1016/j.clml.2019.09.065
    By:
    • Mai, Elias K.;
    • Baertsch, Marc-A.;
    • Hielscher, Thomas;
    • Bertsch, Uta;
    • Schlenzka, Jana;
    • Salwender, Hans J.;
    • Munder, Markus;
    • Fuhrmann, Stephan;
    • Duehrsen, Ulrich;
    • Brossart, Peter;
    • Neben, Kai;
    • Raab, Marc S.;
    • Jauch, Anna;
    • Seckinger, Anja;
    • Hose, Dirk;
    • Luntz, Steffen;
    • Sonneveld, Pieter;
    • Lokhorst, Henk;
    • Martin, Hans;
    • Lindemann, Hans-Walter
    Publication type:
    Article
    39

    Pomalidomide + Bortezomib + Dexamethasone After One Prior Line of Therapy in Bortezomib-Pretreated Multiple Myeloma: Subanalysis of OPTIMISMM.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e32, doi. 10.1016/j.clml.2019.09.048
    By:
    • Dimopoulos, Meletios A.;
    • Weisel, Katja;
    • Moreau, Philippe;
    • Anderson, Larry D.;
    • White, Darrell;
    • San-Miguel, Jesus;
    • Sonneveld, Pieter;
    • Engelhardt, Monika;
    • Jenner, Matthew;
    • Corso, Alessandro;
    • Dürig, Jan;
    • Pavic, Michel;
    • Salomo, Morten;
    • Casalz, Eva;
    • Jiang, Ruiyun;
    • Srinivasan, Shankar;
    • Nguyen, Tuong Vi;
    • Bensmaine, Amine;
    • Peluso, Teresa;
    • Richardson, Paul G.
    Publication type:
    Article
    40

    Prognostic and Predictive Performance of SKY92 Combined with R-ISS in Elderly Multiple Myeloma Patients in The Hovon-87/NMSG-18 Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e10, doi. 10.1016/j.clml.2019.09.014
    By:
    • Kuiper, Rowan;
    • Broijl, Annemiek;
    • van Duin, Mark;
    • van Vliet, Martin H.;
    • Levin, Mark-David;
    • van Beers, Erik H.;
    • Van der Holt, Bronno;
    • Visser, Heleen;
    • Hansson, Markus;
    • van der Velden, Annette W.G.;
    • Dumee, Belinda;
    • Vermeulen, Michael;
    • Koenders, Jasper;
    • Beverloo, H. Berna;
    • Stevens-Kroef, Marian;
    • Sonneveld, Pieter;
    • Waage, Anders;
    • Zweegman, Sonja
    Publication type:
    Article
    41

    Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e2, doi. 10.1016/j.clml.2019.09.004
    By:
    • Sonneveld, Pieter;
    • Attal, Michel;
    • Perrot, Aurore;
    • Hulin, Cyrille;
    • Caillot, Denis;
    • Facon, Thierry;
    • Leleu, Xavier;
    • Belhadj-Merzoug, Karim;
    • Karlin, Lionel;
    • Benboubker, Lofti;
    • Levin, Mark-David;
    • Minnema, Monique;
    • Westerman, Matthijs;
    • Delforge, Michel;
    • Zweegman, Sonja;
    • Pei, Lixia;
    • de Boer, Carla;
    • Vanquickelberghe, Véronique;
    • Kampfenkel, Tobias;
    • Moreau, Philippe
    Publication type:
    Article
    42

    Heavy+Light Chain and Free Light Chain Assays at Baseline and During Follow-up in EMN02/HO95 Multiple Myeloma Clinical Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e47, doi. 10.1016/j.clml.2017.03.084
    By:
    • Omedè, Paola;
    • Redoglia, Valter;
    • Astolfi, Monica;
    • Larocca, Alessandra;
    • Spada, Stefano;
    • Bourlot, Luigi;
    • Cavo, Michele;
    • Petrucci, Maria Teresa;
    • Di Raimondo, Francesco;
    • Patriarca, Francesca;
    • Rambaldi, Alessandro;
    • Rossi, Giuseppe;
    • Ballanti, Stelvio;
    • Gamberi, Barbara;
    • Vincelli, Iolanda Donatella;
    • Grasso, Mariella;
    • Liberati, Anna Marina;
    • Corradini, Paolo;
    • Sonneveld, Pieter;
    • Boccadoro, Mario
    Publication type:
    Article
    43
    44

    Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e145, doi. 10.1016/j.clml.2017.03.261
    By:
    • Weisel, Katja;
    • Dimopoulos, Meletios Athanasios;
    • Van de Donk, Niels;
    • Ramasamy, Karthik;
    • Gamberi, Barbara;
    • Streetly, Matthew;
    • Offidani, Massimo;
    • Bridoux, Frank;
    • Rubia, Javier de la;
    • Kueenburg, Elisabeth;
    • Collins, Shona;
    • Lersch, Frederik;
    • Rosettani, Barbara;
    • Bacon, Pamela;
    • Sonneveld, Pieter
    Publication type:
    Article
    45

    Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e59, doi. 10.1016/j.clml.2017.03.108
    By:
    • Bringhen, Sara;
    • Oliva, Stefania;
    • Liberati, Anna Marina;
    • Belotti, Angelo;
    • Larocca, Alessandra;
    • Bonello, Francesca;
    • Gaidano, Gianluca;
    • Bertazzoni, Paola;
    • Esma, Fabrizio;
    • Stocchi, Raffaella;
    • Malfitano, Alessandra;
    • Ribolla, Rossella;
    • Di Sano, Chiara;
    • Aschero, Simona;
    • Patriarca, Francesca;
    • De Paoli, Lorenzo;
    • Cafro, Anna Maria;
    • Sonneveld, Pieter;
    • Palumbo, Antonio;
    • Boccadoro, Mario
    Publication type:
    Article
    46
    47

    A Multicenter Phase I/II EMN Study of Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e125, doi. 10.1016/j.clml.2017.03.227
    By:
    • Gay, Francesca;
    • Günther, Andreas;
    • Offidani, Massimo;
    • Engelhardt, Monika;
    • Schub, Natalie;
    • Gentili, Silvia;
    • Montefusco, Vittorio;
    • Poenisch, Wolfram;
    • Patriarca, Francesca;
    • Angelucci, Emanuele;
    • Astolfi, Monica;
    • Corradini, Paolo;
    • Einsele, Hermann;
    • Sonneveld, Pieter;
    • Palumbo, Antonio;
    • Gramatzki, Martin
    Publication type:
    Article
    48
    49

    How to Manage Neutropenia in Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 1, p. 5, doi. 10.1016/j.clml.2011.11.001
    By:
    • Palumbo, Antonio;
    • Bladé, Jon;
    • Boccadoro, Mario;
    • Palladino, Carmela;
    • Davies, Faith;
    • Dimopoulos, Meletios;
    • Dmoszynska, Anna;
    • Einsele, Hermann;
    • Moreau, Philippe;
    • Sezer, Orhan;
    • Spencer, Andrew;
    • Sonneveld, Pieter;
    • Miguel, Jesus San
    Publication type:
    Article
    50